Rome, Italy | info@neomatrixbiotech.com |
Personalizing cancer Immunotherapy with our DNA
Running faster than Cancer

Neomatrix mission is to generate the fastest next generation cancer vaccines to selectively eliminate tumor cells in the body.

Our proprietary platform is unique and combines a deep knowledge of cancer biology and Immuno-Oncology, cutting-edge technologies to identify patient’s tumor neoantigens, innovative design and production of fully-synthetic, personalized DNA vaccines, a potent delivery system to maximize the immune response and the synergic effect with immune checkpoint inhibitors.

Latest News

21 November, 2024
Neomatrix Secures EUR 1.5 Million in Funding to Advance Personalized Cancer Vaccine Development

Neomatrix, a pioneering biotech firm, has successfully closed EUR 1.5 million in additional funding led by existing investors 2Invest AG and i2i Capital Limited. This new investment will be crucial in completing the regulatory development for its proprietary personalized cancer vaccines and exploring innovative combination strategies (read more)

8-10 November, 2024
Neomatrix presenting a Poster at SITC’s 39th Annual Meeting

Neomatrix presenting a Poster at SITC’s 39th Annual Meeting, the leading member-driven organization focused on cancer immunotherapy. At SITC’s Annual Meeting, international leaders from academia, regulatory and government agencies, as well as industry (read more)

Where we are

Image

Preclinical studies completed

Image

Biomarker assay under advanced development

Image

Specialty Oncology Centers / KOLs identified and ready to start

Cancer Targets

Image

Melanoma

Image

Lung Cancer

Image
Image This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874958

 

Seal of Excellence - EU Quality Label

Image

Policy

Contact

Image

© 2026 NEOMATRIX SRL | P. IVA 15698291000 | ALL RIGHTS RESERVED